Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartoletti, Michele, Pelizzari, Giacomo, Gerratana, Lorenzo, Bortot, Lucia, Lombardi, Davide, Nicoloso, Milena, Scalone, Simona, Giorda, Giorgio, Baldassarre, Gustavo, Sorio, Roberto, Puglisi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312982/
https://www.ncbi.nlm.nih.gov/pubmed/32471250
http://dx.doi.org/10.3390/ijms21113805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312982/
https://www.ncbi.nlm.nih.gov/pubmed/32471250
http://dx.doi.org/10.3390/ijms21113805

Ejemplares similares